Phase 2 Alzheimer's Disease Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Alzheimer's disease according to the 2024 Alzheimer's Association diagnostic criteria, and whose disease is at a moderate stage.
- People whose score on a standard dementia assessment tool (called the CDR-SB) falls between 9.5 and 15.5.
- People aged between 55 and 80 years old.
- People who have been taking a stable dose of approved Alzheimer's medications (such as donepezil, rivastigmine, galantamine, or memantine, or a combination) for at least 3 months before the screening visit.
- People who have a designated support person (such as a family member or carer) who agrees to participate, spends at least 10 hours per week with them, and can attend study visits or be available by phone at set times.
- People who, in the opinion of the trial investigator, have sufficient ability to read, see, and hear well enough to complete cognitive testing at the time of screening.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a diagnosed brain or nervous system condition other than Alzheimer's disease, or any other condition that has a long-term negative effect on thinking and memory.
- People who cannot have an MRI scan, for example due to metal implants, or who are unable to tolerate the scanning procedure.
- People who have previously been treated with ozanimod or any similar type of medication (called sphingosine-1-phosphate receptor regulators) for Alzheimer's disease before this study.
- People who have significant liver, neurological, lung, eye, hormonal, kidney, or infectious conditions, or other serious illnesses that could interfere with the study or put them at risk, in the opinion of the investigator.
- People with certain heart-related conditions, including: a heart attack, unstable chest pain, stroke, mini-stroke, severe heart failure requiring hospitalisation, or untreated severe sleep apnea within the past 6 months; a resting heart rate below 55 beats per minute or certain heart rhythm problems (unless a pacemaker is in place); or an abnormally long heart electrical interval on an ECG (confirm with trial site for specific values).
- People who have received, or are planning to receive, a live or live-attenuated vaccine within 4 weeks before starting the study treatment, during the study, or within 90 days after finishing the study treatment.
- People who have a history of a serious allergic reaction to any medication, such as severe anaphylaxis or significant liver reactions caused by a drug.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: ＋86 139 0501 6998
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean Absolute Change From Baseline in Brain Amyloid Plaque on 18F-florbetaben PET Scan on Ozanimod Group Versus Control Group; Changes in serum GFAP
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.